June 2024: The Food and Drug Administration has given accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3 T-cell engager, for adult patients with recurr...
bispecific-antibody-therapy
OriCAR-017 for RRMM
A top biopharmaceutical company in the clinical stage, Oricell Therapeutics, shared the long-term follow-up results of OriCAR-017, a Phase I study that looked at how well GPRC5D-t...
bispecific-antibody-therapy